[CAS NO. 1966138-53-3] Coblopasvirdihydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1966138-53-3]

Catalog

HY-117411A

Brand

MCE

CAS

1966138-53-3

DESCRIPTION [1966138-53-3]

Overview

MDL	-
Molecular Weight	855.81
Molecular Formula	C41H52Cl2N8O8
SMILES	O=C(N[C@H](C(N1[C@@H](CCC1)C2=NC(C3=CC=C(C=C3)C4=C5OCOC5=C(C=C4)C6=CNC([C@H]7N(CCC7)C([C@H](C(C)C)NC(OC)=O)=O)=N6)=CN2)=O)C(C)C)OC.[H]Cl.[H]Cl

For research use only. We do not sell to patients.

Summary

Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03995485	Kawin Technology Share-holding Co., Ltd.\|KawinGreen Biotech Co., Ltd.	Hepatitis C, Chronic	June 7, 2017	Phase 3
NCT03416491	Kawin Technology Share-holding Co., Ltd.\|KawinGreen Biotech Co., Ltd.	Hepatitis C, Chronic	February 15, 2017	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 58.42 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1685 mL	5.8424 mL	11.6848 mL
5 mM	0.2337 mL	1.1685 mL	2.3370 mL
10 mM	0.1168 mL	0.5842 mL	1.1685 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Gao Y, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. Liver Int. 2020;40(11):2685-2693.